Clinical trials: Targeted Therapy
Radicular; Neuropathic, Cervical, Neck Pain
C7-T1 Epidural Steroid Injections Versus Targeted Injection for Treatment of Cervical Radicular Pain
Cervical radicular pain is a common, disabling problem, occurs in 83:100,000 individuals per year. Symptoms are most often caused by intervertebral disc herniation (21.9%) or central or foraminal stenosis from spondylosis…
- Trial name
- NCT02095197
- Testing
- Triamcinolone 80mg
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Northwestern University
Severe Combined Immunodeficiency, X-Linked
Lentiviral Gene Therapy for X-linked Severe Combined Immunodeficiency
Severe combined immunodeficiency disorder (SCID) is a heterogeneous group of inherited disorders characterized by a profound reduction or absence of T lymphocyte function, resulting in lack of both cellular and humoral immunity.
- Trial name
- NCT03601286
- Testing
- Lentiviral vector transduced CD34+ cells
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Elevated Anxiety Sensitivity
Exposure Therapy Consortium (ETC) for Anxiety Sensitivity
The current study seeks to test differences between a single-session large-group format of standard exposure, enhanced exposure, and a control condition in treating anxiety sensitivity.
- Trial name
- ETC (NCT05225740)
- Testing
- Standard Exposure, Stress Management Training, Enhanced Exposure
- Where
- 12 sites in United States, Australia and 2 more
- Volunteers
- 399 people, healthy volunteers welcome
- Sponsor
- University of Texas at Austin
Cardiovascular Disorder
Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150)
Collecting local data, safety and experience trial.
- Trial name
- NCT00652717
- Testing
- Ezetimibe, simvastatin
- Volunteers
- 280 people
- Sponsor
- Organon and Co
Patient Readmission
Transition cAre inteRvention tarGeted to High-risk patiEnts To Reduce rEADmission
Hospital rehospitalizations within 30 days are frequent and represent a burden for the patients, but also for the entire health care system.
- Trial name
- TARGET-READ (NCT03496896)
- Testing
- TARGET
- Where
- 4 sites in Switzerland
- Volunteers
- 1,393 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Liver Cancer
Development of a Risk Prediction Model for Immune-Targeted Therapy-Related Diarrhea in Patients With Hepatocellular Carcinoma Based on TCM Constitutional Types: A Prospective Cohort Study
Immune checkpoint inhibitors combined with anti-angiogenic targeted agents have become the first-line standard therapeutic regimen for advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07741903
- Volunteers
- 500 people
- Sponsor
- Affiliated Hospital of Chengde Medical University
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer
This phase II trial studies how well giving paclitaxel albumin-stabilized nanoparticle (Nab-paclitaxel) formulation together with bevacizumab followed by bevacizumab and erlotinib hydrochloride work in treating patients with…
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Recurrent Breast Cancer
- Trial name
- NCT00733408
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, bevacizumab, erlotinib hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 59 people
- Sponsor
- University of Washington
Breast Cancer, Lung Cancer
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Head and Neck Cancer
- Trial name
- POSITive (NCT06321640)
- Testing
- Cohort A: primarily operable disease, candidate to adjuvant, Cohort B: locally advanced disease, Cohort C: metastatic disease
- Where
- Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Melanoma
Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence
Cutaneous melanoma is a tumor with a serious evolution if its initial diagnosis is late. Since 2011, the treatment of advanced forms involves two therapeutic approaches : targeted therapies (BRAF and MEK inhibitors) if the tumor…
- Trial name
- NAKIMEL (NCT05062096)
- Testing
- Blood samples, Skin biopsy
- Volunteers
- 220 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Tuberous Sclerosis, Subependymal Giant Cell Astrocytoma
Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex
The purpose of the study is to evaluate the safety and potential side effects of everolimus (an experimental drug) on a person with Tuberous Sclerosis Complex who also has been diagnosed with a brain tumor (astrocytoma) The…
- Trial name
- NCT00411619
- Testing
- Everolimus
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Ovarian Cancer
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
The purpose of this study is to determine if either of two doses of EMD 273066 when given with a low dose of cyclophosphamide will result in a second time to progression that is as long or longer than the first time to progression
- Trial name
- NCT00408967
- Testing
- Tucotuzumab celmoleukin (EMD 273066)
- Sponsor
- EMD Serono
Renal Cancer
Vascular Targeted Photodynamic Therapy T1a Renal Tumours
Vascular Targeted Photodynamic therapy (VTP) with the Vascular Occluding Agent (VOA) WST11, may offer an alternative, providing tumour destruction via a minimally invasive approach.
- Trial name
- KCM201 (NCT01573156)
- Testing
- Light activated WST11
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- University of Oxford
Plantar Fasciitis, Chronic, Pain
The Therapeutic Effect of Targeted Intrinsic Foot Muscles Exercises in Plantar Fasciitis
A reduction of intrinsic foot muscle sizes has been identified in patients with chronic plantar fasciitis. Weaker intrinsic foot muscles has been suggested to decrease the medial longitudinal arch height and subsequently increase…
- Trial name
- NCT05455645
- Testing
- targeted intrinsic foot muscle exercises
- Where
- Hong Kong
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Multiple Myeloma
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
This study will test the safety of the study treatment, MCARH109, at different doses, to see which dose is safest in people, and to look for any good and bad effects of this treatment.
- Trial name
- NCT04555551
- Testing
- Infusion of MCARH109 T cells
- Where
- 7 sites in United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HIV, Medication Adherence
Intervention Targeting Substance Using Older Adults With HIV
The proposed study uses a randomized controlled experimental design to evaluate the efficacy of a brief intervention using spiritual self schema (3S+) counseling to simultaneously target HIV health outcomes, and substance use…
- Conditions
- HIV, Medication Adherence, Substance Dependence
- Trial name
- NCT01305629
- Testing
- Spiritual Self-Schema Therapy
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Hunter College of City University of New York
Target Vessel Failure in Saphenous Vein Grafts, Percutaneous Coronary Intervention
Native Coronary Artery Instead of SAphenous Vein Graft Intervention for Treatment of Significant Saphenous Vein Graft Lesions
The primary study objective of the NASA registry is to evaluate the 12-month incidence of target vessel failure (TVF) in patients who present with saphenous vein graft (SVG) lesions and undergo percutaneous coronary intervention…
- Trial name
- NCT05187351
- Testing
- Percutaneous coronary intervention of the native coronary artery with Synergy
- Where
- 2 sites in United States
- Volunteers
- 99 people
- Sponsor
- Minneapolis Heart Institute Foundation
Non-small Cell Lung Cancer (NSCLC) With Brain Metastases
GRN1005 in Non-Small Cell Lung Cancer (NSCLC) Patients With Brain Metastases (GRABM-L)
The purpose of this study is to assess the efficacy, safety, and tolerability of GRN1005 in patients with brain metastases from non-small cell lung cancer (NSCLC).
- Trial name
- GRABM-L (NCT01497665)
- Testing
- GRN1005
- Where
- 10 sites in United States, Canada
- Volunteers
- 16 people
- Sponsor
- Angiochem Inc
Breast Cancer
Genome Sequencing in Refractory Breast Cancer to Molecular Targeted Therapy and Young Breast Cancer
The purpose of this study is to investigate and analyse genomic profiles in patient with breast cancer who failed standard treatment, refractory and young breast cancer.
- Trial name
- NCT02597179
- Where
- South Korea
- Volunteers
- 350 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
The purpose of this study is to evaluate the safety and efficacy of allogeneic γδ T cells combined with targeted therapy and PD-1 monoclonal antibody in patients with hepatocellular carcinoma resistant to PD-1 monoclonal…
- Trial name
- NCT06364800
- Testing
- γδ T cells, PD-1 monoclonal antibody, targeted drugs
- Volunteers
- 18 people
- Sponsor
- Beijing 302 Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.